6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata. 2020

Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.

l-DOPA-induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT1A partial agonist) have shown promising results in the treatment of PD and LID, however no 5-HT-based treatment has been approved in PD. The present study was aimed to investigate how the substantia nigra pars reticulata (SNr) is affected by buspirone and whether it is a good target to study 5-HT antidyskinetic treatments. Buspirone was studied using in vivo single-unit, electrocorticogram, local field potential recordings along with microdialysis and immunohistochemistry in naïve/sham, 6-hydroxydopamine (6-OHDA)-lesioned or 6-OHDA-lesioned and l-DOPA-treated (6-OHDA/l-DOPA) rats. Local buspirone inhibited SNr neuron activity in all groups. However, systemic buspirone reduced burst activity in 6-OHDA-lesioned rats (with or without l-DOPA treatment), whereas 8-OH-DPAT, a full 5-HT1A agonist induced larger inhibitory effects in sham animals. Neither buspirone nor 8-OH-DPAT markedly modified the low-frequency oscillatory activity in the SNr or synchronization within the SNr with the cortex. In addition, local perfusion of buspirone increased GABA and glutamate release in the SNr of naïve and 6-OHDA-lesioned rats but no effect in 6-OHDA/l-DOPA rats. In the 6-OHDA/l-DOPA group, increased 5-HT transporter and decreased 5-HT1A receptor expression was found. The effects of buspirone in SNr are influenced by dopamine loss and l-DOPA treatment. The present results suggest that the regulation of burst activity of the SNr induced by DA loss may be a good target to test new drugs for the treatment of PD and LID.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D002065 Buspirone An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM. Anxut,Apo-Buspirone,Bespar,Busp,Buspar,Buspirone Hydrochloride,Gen-Buspirone,Lin-Buspirone,MJ-9022-1,N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide,Neurosine,Novo-Buspirone,Nu-Buspirone,PMS-Buspirone,Ratio-Buspirone,Apo Buspirone,Gen Buspirone,Hydrochloride, Buspirone,Lin Buspirone,MJ 9022 1,MJ90221,Novo Buspirone,Nu Buspirone,PMS Buspirone,Ratio Buspirone
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras
D016627 Oxidopamine A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals. 6-Hydroxydopamine,6-OHDA,Oxidopamine Hydrobromide,Oxidopamine Hydrochloride,6 Hydroxydopamine,Hydrobromide, Oxidopamine,Hydrochloride, Oxidopamine
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D065841 Pars Reticulata A region in the substantia nigra located ventral and lateral to the PARS COMPACTA. Pars Lateralis,Pars Reticularis,Substantia Nigra Pars Lateralis,Substantia Nigra Pars Reticulata,Substantia Nigra Reticulata,Substantia Nigra, Pars Reticulata,Laterali, Pars,Lateralis, Pars,Nigra Reticulata, Substantia,Nigra Reticulatas, Substantia,Pars Laterali,Pars Reticulari,Pars Reticulatas,Reticulari, Pars,Reticularis, Pars,Reticulata, Pars,Reticulata, Substantia Nigra,Reticulatas, Pars,Reticulatas, Substantia Nigra,Substantia Nigra Reticulatas

Related Publications

Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
October 2006, The European journal of neuroscience,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
September 2000, Brain research,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
June 1986, Neuroscience letters,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
February 2009, Brain : a journal of neurology,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
April 2003, Brain research bulletin,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
July 1997, Brain research,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
July 1990, Brain research,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
July 2013, Synapse (New York, N.Y.),
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
March 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration,
Sergio Vegas-Suárez, and Clarissa Anna Pisanò, and Catalina Requejo, and Harkaitz Bengoetxea, and Jose Vicente Lafuente, and Michele Morari, and Cristina Miguelez, and Luisa Ugedo
January 1995, Epilepsy research,
Copied contents to your clipboard!